Background: O6-methylguanine-DNA methyltransferase promoter methylation (mMGMT) in Glioblastoma (GB) is a predictive indicator of better survival and responsive to temozolomide (TMZ). Clinically, TMZ is used for all patients with good performance status irrespective of mMGMT due to observed benefit in some patients with unmethylated tumors. A 9% mMGMT cut-off was analytical validated for a Methylation-specific restriction enzyme quantitative PCR. We aim to evaluate the current cut-off in context of patient outcomes and to query a cut-off with more clinical relevance.
Design: Twenty-two cases of UM were retrieved from the ocular pathology laboratory archive. Automated immunohistochemistry for CITED1 was performed, and whole digital slides were acquired using the Philips IntelliSite scanner. Clinicopathologic features, such as age at diagnosis, tumor dimension, prior radiation treatment, follow-up and immunoreactivity scores (IRS; % of positive cells x intensity) for CITED1 were evaluated for all cases. Statistical correlations were performed using the SPSS software.
Results: CITED1 was expressed in 100% of malignant cells, regardless of prior radiation treatment (5/22 cases) and tumor dimension (mean: 12 mm). Kaplan-Meier survival curves using the Log-rank test showed a positive correlation between CITED1 IRS and the occurrence of metastasis (p=0.04). In contrast, normal choroidal melanocytes adjacent to the tumor did not express CITED1.
Conclusions: Our results demonstrate an association between higher CITED1 expression in UM and a greater risk of metastatic disease. Moreover, the lack of correlation between levels of CITED1 expression and tumor dimensions suggests that CITED1 is not directly linked to growth of the tumor.
The expression of CITED1 only in malignant melanocytes proposes a possible mechanism by which tumor cells may undergo MAT prior to entering the systemic circulation. Further in vitro characterization of CITED1 regulated tumor evasion in uveal melanoma is required to support this hypothesis.
High Grade Gliomas Involving The Subventricular
Zone -A Molecular Study of 32 cases 
Prince of Wales Hosp, Shatin
Background: High grade gliomas abutting on the subventricular region have been described to show aggressive features and poor outcomes but there has been no detailed study of the molecular features of these tumors.
Design:
We studied 32 such tumors from our archives, all except one being glioblastomas, for their clinical features and tested them for amplification of c-myc, MYCN, EGFR, mutations of H3F3A-K27M, TERTp, IDH1-R132H, deletion of 10q, and by immunohistochemistry ATRX, nestin and SOX2.
Results: c-Myc and MYCN were each amplified in 32.3% of cases and together were amplified 58% of the cases. This is in contrast to information derived from known TCGA glioblastoma data set where c-Myc and MYCN were only rarely amplified in glioblastoma. MYCN in addition was associated with younger age (p=0.029), concomitant H3F3A-K27M mutation (p=0.002), non-amplified EGFR (p=0.023) and mid-line location (p=0.012). Interestingly, we found a low percentage of TERTp mutation (19%) among these high grade gliomas which was mutually exclusive with a higher frequency of loss of ATRX expression (p=0.025). The majority (91%) of tumors were IDH wild type and 39% of them were deleted for 10q. Moreover, 97% of cases expressed at least one of the stem cell markers, which may be related to the supposedly subventricular location of neural stem cells. 89% of cases relapsed with 50% showing CSF dissemination. However, there was no statistical relationship between survivals and biomarkers or other clinical parameters.
Conclusions:
In conclusion, our study has identified a subgroup of subventricular zone high grade gliomas characterized by c-Myc, MYCN amplification and frequent expression of stem cell markers and a high rate of CSF dissemination.
Decreased CIC and FUBP1 Expressions Are Associated with Poor Prognosis in Anaplastic Astrocytomas
Yen-Ying Chen Design: One hundred and forty-five patients with primary anaplastic astrocytomas who had adequate follow-up data were included in the study. The expressions of CIC and FUBP1 were evaluated by immunohistochemistry. The results were correlated with the survival of the patients.
Results: Decreased CIC and FUBP1 protein expressions, defined as <50% of tumor cells staining, were identified in 37.9% (55/145) and 42.1% (61/145) of anaplastic astrocytomas, respectively. The 1p and 19q status evaluated by fluorescence in situ hybridization was not significantly associated with the protein expression for both genes. Decreased CIC and FUBP1 expressions were significantly associated with shorter overall survival (p < 0.001 and p = 0.002, respectively). Their impact on survival remained statistically significant in the multivariate analyses with adjustment of age, gender, extent of resection, bevacizumab/temozolomide treatment, IDH1/2 mutation status and ATRX expression (p = 0.002 and p = 0.013 for CIC and FUBP1, respectively). Background: Hsa-mir-21 is the most frequently overexpressed microRNA in glioblastoma and many other human cancers. Our previous studies show that high miR-21 expression is associated with high proliferation, low apoptosis, high invasion and metastatic potential of multiple cancer cells and promotes oncogenesis. MicroRNA in situ hybridization has been approved to efficiently detect in situ expression of miRNA within FFPE tissue. Here we investigated in situ expression of miR-21 within low or high glioma as well as normal brain tissue and explored its potential diagnosis role.
Design:
We selected 24 cases of high-grade gliomas, 14 cases of lowgrade gliomas and 14 cases of autopsy brain cortex without gross pathological changes and incorporated representative tissue (1mm in diameter) into a tissue microarray. In situ hybridization staining performed on Xmatrx automated system using FAM-labeled miRNA probes (BioGenex, CA) for miR-21 was performed on tissue array. The H&E quality and in situ hybridization results were independently reviewed by two pathologists. The hybridization intensity, percentage of positive cells, identity of positive cells were documented and analyzed.
Results: miR-21 shows variable weak hybridization ( including cytoplasmic and nuclear) in normal human organ tissue. In our high grade glioma cohort, 60% of gliomas show intense nuclear staining in more than 90% of tumor cells and the remaining 40% show moderate to intense nuclear stain in at least 50% tumor cells. In contrast, miR-21 shows variable hybridization pattern in low grade gliomas and normal brain tissue. Representative results of miR-21 in situ hybridization is shown in Figure 1 . Interestingly, endothelial cells within both low and high grade glioma show moderate to intense miR21 expression.
Conclusions: In the current study, we confirmed the overexpression of miR-21 by in situ hybridization in FFPE high grade glioma tissue. Our study also provided experimental evidence of the importance of miR-21 expression pattern during gliomagenesis. miR-21 can serve as potential actionable target in the therapy of high grade gliomas. Background: Craniopharyngiomas are epithelial neoplasms of the sellar/parasellar region which are hypothesized to arise from developmental derivatives of the stomodeal ectoderm and Rathke's pouch. Adamantinomatous craniopharyngiomas (ACP) occur in all age groups, whereas papillary craniopharyngiomas (PCP) occur almost exclusively in adults. Craniopharyngiomas have excellent long-term survival, but both subtypes are associated with profound morbidity including hypothalamic and endocrine dysfunction, which are often exacerbated by surgery, and recurrences are common. BRAF V600E mutations in PCP render them susceptible to BRAF/MEK inhibitors, but effective targeted therapies are not available for ACP.
Design: We quantified and mapped PD-L1 and PD-1 expression in 23 ACP and 18 PCP resection specimens using immunohistochemistry and immunofluorescence and confirmed expression with RNA in situ hybridization. We used multiplexed cyclic immunofluorescence (CyCIF) to map the spatial distribution and density of immune infiltrates and characterized cell cycle and signaling pathways in ACP tumor cells with intrinsic expression of PD-1.
Results: All adamantinomatous (23/23; 100%) and papillary (18/18; 100%) craniopharyngiomas expressed PD-L1. In ACP, PD-L1 was predominantly expressed by tumor cells comprising the cyst lining. In PCP, PD-L1 was highly-expressed by tumor cells surrounding stromal/ fibrovascular cores. ACP also invariably showed membranous tumor cell intrinsic PD-1 expression in whorled epithelial cells with nucleartranslocated beta-catenin. These cells exhibited increased pERK and pS6, suggestive of activation of intracellular signaling downstream of PD-1. Cells with membranous PD-L2 expression were identified in close association with the PD-1 positive whorls. Quantitative and spatial profiling of immune populations showed a modest density of tumor infiltrating CD8+ cytotoxic T cells, low densities of PD-L1+ macrophages and FOXP3+ regulatory T-cells, and enrichment of immune populations in the peritumoral/stromal compartment.
Conclusions: ACP exhibit intrinsic PD-L1 expression in the tumor cyst lining and intrinsic PD-1 expression in the proposed oncogenic stemlike population of whorled epithelial cells with nuclear-translocated beta-catenin. In PCP, proliferative basally oriented tumor cells strongly express PD-L1 in a continuous band at the stromal-epithelial interface. Targeting PD-L1 and/or PD-1 in both subtypes of craniopharyngioma might therefore be a valuable therapeutic strategy. Recurrence-free and overall survival at 10 years were respectively 73% (95% CI:65-82) and 65% (95% CI:52-77). 39 patients had at least 1 recurrence after their baseline date, 9 had metastases and 2 both. 32 patients died. On univariate analysis WHO CNS and Soft Tissue grade were significantly associated with recurrence-free (p-value respectively 0.015 and 0.0039) but not overall survival, as was necrosis (p=0.0013). Recurrence-free survival at 10 years was respectively 59.4, 54.9 and 32.1% for CNS WHO grade 1,2 and 3 versus 55.9 and 32.1% for Soft Tissue WHO SFT and malignant SFT. Recurrence-free survival at 10 years was respectively 0% and 53.3% for tumors with and without necrosis.
Conclusions: SFT/HPC is a tumor with high frequency of recurrence and a tendency to metastasize. Grading is significantly associated with recurrence-free but not overall survival. In both grading schemes, SFT/ HPC can be stratified into two grades, with the additional WHO CNS grade not appearing to be of prognostic significance. The importance of necrosis as a grading criteria needs to be further explored. Background: Choroid plexus tumors (CPT) are rare primary CNS tumors that include the WHO Grade 1 papilloma (CPP), the Grade 2 atypical papilloma (ACPP) and the Grade 3 carcinoma (CPC). In this study, we used a hybrid capture based comprehensive genomic profiling assay (CGP), to define the genomic alterations (GA) in clinically aggressive CPT and correlated the findings with clinicopathologic variables.
Design: DNA was extracted from 40 microns of FFPE specimen from 27 cases of relapsed, refractory CPT. CGP was performed using a hybrid-capture, adaptor ligation based next generation sequencing assay to a mean coverage depth of 630X. Tumor mutational burden (TMB) was determined on 1.1 Mbp of sequenced DNA and microsatellite instability (MSI) was determined on 114 loci. The results were analyzed for all classes of genomic alterations (GA), including base substitutions, insertions and deletions (short variants; SV), fusions, and copy number changes including amplifications (amp) and homozygous deletions.
Results: Clinicopathologic features and GA results are shown in the Table. CPP had a low KI67 index, low 0.7 GA/tumor, absent oncogene (OG) and tumor suppressor (TS) and TMB, but featured significant TERT mutations suggesting methylation silencing events. Results: NHERF1 decorates the membrane of intracytoplasmic lumens and microlumens in the secretory variant, consistent with a previously described epithelial differentiation of this subtype. NHERF1 also labels microlumens in chordoid meningioma, a epithelial variant not previously known to harbor these structures. Ultrastructural analysis confirmed the presence of microlumens with microvilli projecting into the lumen. NHERF1 associates with the ezrin-radixinmoesin (ERM)-NF2 cytoskeletal proteins, and moesin but not NF2 was detectable in the microlumens. NHERF1 revealed microlumens in 87% of the chordoid meningioma and meningioma with chordoid component cases, and in 100% of the secretory meningioma cases. Design: We retrospectively analyzed cases from TCS surgeries performed in the same institution over a 2.5 year period (January 2015 to July 2017). We reviewed the H&E slides by light microscopy and looked for presence/absence of fat, fibrovascular tissue, nerve bundles and ependymal tissue. In addition, we semiquantitatively assessed the proportion of different histologic elements. We divided the patients according to age, into seven groups: <1-year-old, 1-2-year-old, 2-3-year-old, 4-5-year-old, 6-7-year-old, 8-9-year-old, and 10-16-year-old.
Results:
We identified 114 cases. The mean patient age was 5.2 years (range 3 months-16 years); 67 (59%) of the patients were females. Fibrovascular tissue was consistently present and associated with variable amounts of fat (57% of cases). Small amounts of ependymal tissue were variably present (32% of cases). Presence of nerve bundles was frequently seen (91%). The presence of fat was more frequently observed in young patients (0-4 years). In individual biopsies, the proportion of fat shows marked variation, ranging from 0-95%, and was higher in young patients (0-7 years). The frequency of ependymal tissue was 46% in young patients (0-9 years), but rare in older patients (10-16 years). Results: In all ten prion disease cases, PrP Sc deposits were observed in the retina by immunohistochemistry. PrP Sc was limited to the outer and inner plexiform layers of the retina and was most prominent in the outer plexiform layer, with the majority of cases exhibiting coarse, 5-10 um well-aligned ovoid deposits. In the sclera, cornea, lens, and optic nerve, no deposits were observed.
Conclusions

Conclusions: PrP
Sc deposits were present consistently in the retina of patients with prion disease and can be detected immunohistochemically. Our findings confirm previous isolated reports of retinal PrP Sc expression in the largest series of documented prion cases to date. We suggest that the retina potentially serves as a diagnostic target in clinically suspected prion disease. Additionally, retinal involvement may contribute to visual symptoms commonly associated with prion disease.
1
Houston Methodist Hospital, Houston, TX Background: Next generation sequencing (NGS) is an established technology which is currently being used for diagnostic and therapeutic purposes in myeloid and lymphoid neoplasms. Vitreoretinal lymphomas (VRL) are a rare form of primary CNS lymphoma. Prognosis is generally poor and outcomes can include loss of vision, CNS involvement, local, and systemic recurrences. Optimal therapy is uncertain and usual therapeutic options include external beam radiation and local and systemic chemotherapy. Targeted novel therapies may better treat or control this type of lymphoma. We report our experience using small-volume vitreous fluid biopsies for NGS of VRL.
Design:
We collected diluted and undiluted vitreous specimens from 3 patients with VRL. DNA extractions were performed on 50 microL of specimen and subjected to the 54 gene TruSight DNA Amplicon Myeloid Sequencing. A minimum of 100x read depth coverage is required at a given base for the interpretation of wild-type or variant. The limit of detection is 10% mutant alleles at 100X coverage. Variants are determined relative to the reference human genome hg19. Cytological analysis was performed with immunohistochemical confirmation.
Results: The corresponding cytological diagnosis was that of diffuse large B cell lymphoma (DLBCL) in all three patients. Using NGS, we identified variants in two of the three patient. In patient #1's sample, MYD88 Leu265Pro was present. This is a known somatic gainof-function mutation that is potentially targetable. It is frequently associated with decreased overall survival and a prognosis similar to ABC type DLBCL. Patient #1's sample also had a DNMT3A variant. Patient #2's sample (Cyclin D1-positive DLBCL) had 3 TP53 variants (Val216Ala, Asn131Ile, and Ser99Phe) which are confirmed somatic mutations and are associated with poor prognosis. TP53 mutated B cell lymphomas can potentially be targeted by Ibrutinib. In addition, several other variants were identified involving DNMT3A, CBL, and KRAS. Patient #3 had no identifiable mutations.
Conclusions:
We have demonstrated the feasibility of performing a basic NGS panel on very small-volume vitreous fluid biopsies in vitreoretinal lymphomas. While more studies are needed, this approach can potentially provide valuable information that can be utilized for supporting diagnosis, prognostication, therapeutic targeting and disease monitoring. Background: One of the main prognostic factors in meningiomas is the occurrence of a tumor recurrence. According to the WHO classification, aggressive meningiomas show higher mitotic and Ki67 indices than benign ones. Thus, deregulation of the cell cycle could be a mechanism involved in the aggressiveness of some meningiomas. In this study, we investigated somatic molecular alterations of genes regulating the cell cycle.
Design: Using next generation sequencing technique, we studied 84 genes involved in cell cycle regulation in a series of 30 meningiomas, 13 non-recurrent (7 grade I, 5 grade II and 1 grade III) and 17 recurrent (4 grade I, 5 grade II and 8 grade III). Results of the molecular analysis, WHO grade and Ki67 index were analyzed with respect to the presence or not of a tumor recurrence and progression free survival (PFS).
Results: Among the molecular alterations found, the analysis identified in 5 cases, a SNV (Single Nucleotide Variation) on CDKN2A gene (NM_000077, exon2, c.G442A, p.Ala148Thr) that was significantly associated with meningiomas recurrence (p=0.05). This mutation, confirmed by Sanger sequencing, is referenced in the COSMIC database (Catalog of Somatic Mutations in Cancer) in some other tumors (melanomas, renal clear cell carcinomas and pancreatic adenocarcinomas) but has not been reported in meningiomas. On immunohistochemical study, the expression of p16 (CDKN2A) was absent or very weak in all the cases harboring the CDKN2A p.Ala148Thr mutation. However, the analysis of the whole series did not show any significant relation between p16 expression and tumor recurrence. Mean follow-up was 60±75 months and mean PFS 75±73 months. PFS was shorter in grade II and III vs. grade I meningiomas (p=0.002) and, in tumors with a mitotic index ≥ 4 (p=0.03) and a Ki67 index > 5% (p=0.047). Presence or absence of the CDKN2A p.Ala148Thr mutation had no influence on PFS.
Conclusions: Our study identified a novel mutation of CDKN2A potentially involved in meningiomas recurrence. However, the physiopathological role of this alteration remains to be clarified. In addition, it would be interesting to know whether this mutation is associated with other alterations of genes regulating the cell cycle and, if so, how they could cooperate.
PREVIOUSLY PUBLISHED 1826 BRAF, NRAS and PIK3CA Mutations in Cases of
Orbital Erdheim-Chester Disease Design: Institutional files (1990-2016) search identified 20 cases with diagnosis of orbital ECD, xanthogranulomatous infiltrate and xanthogranuloma. Cases were reviewed and diagnosis of ECD was made in 5 cases. Clinical information was collected. All cases were screened for BRAF V600E mutation by IHC. Next generation sequencing was performed to detect BRAF, NRAS and PIK3CA mutations.
Results: 3 M and 2 F with age ranging from 50-75 years (mean 61) were identified. Orbital presentation varied from diplopia/proptosis (n=1), tearing/eyelid swelling (n=1), fluctuating vision/eye irritation (n=1) or recurrent xanthelasma (n=1). One case had no ophthalmic symptoms and the bilateral masses were incidentally found on a brain MRI. On the imaging, all cases had bilateral intraconal orbital masses or infiltrates. Other organs involved were: perinephric soft tissue (3/5), paranasal sinus (3/5), brain (3/5), lung (2/5), peritoneum (1/5), bone (1/5). One case had diabetes insipidus. The follow-up duration ranged from 5-84 months (mean; 40.2). Two cases with molecularly confirmed BRAF V600E mutations were treated with vemurafenib. One had dramatic response resulting in no residual disease, the otherstopped treatment due to severe drug reaction. Two cases received chemotherapy and immunosuppression. On the last follow up, 4 patients were alive with disease and 1 was alive without disease. All cases were positive for BRAF V600E on IHC. Two cases did not have sufficient DNA for sequencing. The 3 remaining cases had BRAF V600E mutation by sequencing, one harbored a TET2 gene mutation and clinically had concomitant CMML. We did not identify mutations on NRAS or PIK3CA genes.
Conclusions: In our study, BRAF V600E mutation was identified in all cases by IHC and in 3 cases with sufficient DNA for genome sequencing. A complete response was achieved in the patient who received vemurafenib. NRAS and PIK3CA mutations were not detected in our cases. Albeit this is a small case series, the alternative mutations were only seen in a small subset of cases in prior studies. Medical University of South Carolina, Charleston, SC Background: Endolymphatic sac tumor (ELST) is an extremely rare neoplasm arising in the temporal petrous region thought to originate from endolymphatic sac epithelium and only recently recognized as a distinct entity. It may arise sporadically or in association with VonHippel-Lindau syndrome (VHL). The ELST prevalence in VHL ranges from 3-16% and may be the initial presentation of the disease. Onset is usually in the 3rd to 5th decade with hearing loss and an indolent course. ELSTs present as locally destructive lesions with characteristic CT imaging features and histology with papillary, cystic or glandular architectures. They immunoexpress keratin, EMA, and variably S-100, GFAP, and NSE. Currently it is recommended that given its rarity, ELST needs to be differentiated from other entities with similar morphohistologic patterns, including metastatic renal cell carcinoma (RCC).
Design: Four sporadic ELST cases were evaluated with immunohistochemistry and single nucleotide polymorphism microarray testing. Comparison with the RCC immunophenotype and copy number profiles was performed.
Results: Four adult patients presented with characteristic destructive lesions in the petrous temporal bones without clinical evidence of VHL including the presence of other VHL-related tumors (i.e. RCC, hemangioblastomas). Full VHL gene sequencing was previously performed in one patient with wild-type results. Pathology of tumors showed characteristic ELST morphology with immunoexpression of CK7, GFAP, PAX-8, PAX-2, CA9 in the tumor cells. RCC marker, CD10, GATA3, CK20, S100, chromogranin, synaptophysin, SMA, TTF1, thyroglobulin, transthyretin were negative in the tumor cells. Preliminary molecular testing showed loss of 3p (including the VHL gene), 4q, and 9p.
Conclusions: Immunoreactivity for renal markers in ELST is an important diagnostic caveat and has not been previously reported. In fact, renal markers are currently recommended in order to rule out metastatic RCC; however, there is evidence to suggest that PAX gene complex and CA9 have been implicated in the development of the inner ear. Importantly, genotyping of ELST has not been previously reported, and loss of 3p (which includes the VHL locus) in ELST suggests similar mechanistic origins as RCC. We are currently expanding our cohort of cases to confirm these novel findings.
Transcriptomic Analysis Reveals Astroblastomas that Cluster with HGNET-BCOR not HGNET-MN1
Bette Kleinschmidt-DeMasters th group. Astroblastomas were found in the original study exclusively in the HGNET-MN1 group. RNA assessment by transcriptomic analysis (microarray gene chip) can also show this grouping and generally correlates well with histopathological diagnosis, as does DNA methylation. Within our dataset we hypothesized that cases from our files previously-diagnosed as astroblastoma would cluster as HGNET-MN1 and medulloepitheliomas/ embryonal tumor with abundant neuropil and true rosettes would cluster tightly as a distinct group.
Design: Affymetrix microarray transcriptomic data from file cases of histologically-diagnosed CNS-PNET, astroblastoma, or ETMR. Unsupervised hierarchical clustering analysis was performed using R bioinformatics.
Results: 22 pediatric tumors met inclusion criteria. Signature transcripts for each subgroup as identified by Sturm et al grouped 5 of 6 astroblastoma-histology tumors as HGNET-MN1. The 6th, however, was high grade, albeit histologically-classic, and developed metastases with 8 months; both original and metastatic samples closely clustered with HGNET-BCOR tumors in our dataset. All 6 ETMRs (all LIN28a IHC+) clustered tightly together; these tumors had original histological diagnoses of medulloepithelioma (n=1) or embryonal tumor with abundant neuropil and true rosettes (ETMR) (n=4), and thus, clustering was as expected. However, 1 of 6, even on histological review, remained a relatively patternless PNET-like small blue cell tumor without rosettes and was proven to be ETMR only by transcriptomic analysis + LIN28a IHC+. Samples that grouped into EFT-CIC (n=1), NB-FOXR2 (n=6), and HGNET-BCOR (n=3) were less distinctive histologically.
Conclusions:
Transcriptomic analysis reveals occasional astroblastomas that cluster as HGNET-BCOR rather than HGNET-MN1. 
Design:
We encountered eleven cases of anaplastic myxopapillary ependymomas from five institutions. By definition, they included at least two anaplastic features: > 5 mitoses per 10 high power fields, MIB-1 labeling index (LI) > 10%, microvascular proliferation, or necrosis, typically in foci of hypercellularity and reduced mucin.
Results: There were 6 male and 5 female patients (age range 6-57 years; median 32 years). Seven displayed anaplasia at initial resection, while four became anaplastic at the time of recurrence, 9 months to 14 years subsequently. The maximal mitotic index ranged from 3 to 20 (median 7). The MIB-1 LI ranged from 8.5-40%, with the LI in foci of classic MPE typically being <3%. There was CSF dissemination in 8/11 cases, documented recurrence after anaplasia in four cases, and invasion of adjacent bone/soft tissues in four cases. One case had metastatic disease to the lung.
Conclusions:
Although rare, features of anaplasia can be found in both pediatric and adult MPEs, similar to other ependymomas. At a minimum, closer clinical observation is recommended, given the more aggressive biologic potential. Further study is needed to determine WHO grading implications.
1830 Identifying epithelial-mesenchymal transition (EMT) factor in relation with tumor progression and therapeutic resistance of malignant glioma Chohnam National University Hwasun Hospital, Hwasun-gun, Jeollanam-do Background: Glioblastoma is the most aggressive form of brain tumors, as they are growing fast and prone to infiltrate into the surrounding parenchyma. The current treatment is surgery to remove the tumor as much as possible, in combination with chemoradiation. Invasive phenotype and cancer stemness that promote resurgence of residual tumor cells is the major obstacle in glioblastoma treatment. Hence identifying primary factor of epithelial-mesenchymal transition (EMT) related with invasion and stemness of glioblastoma is critical in setting a therapeutic strategy.
Design: Hypermotile glioma cell lines were established through a repetitive scratch method using U87, U251, and U118 cell lines. Then altered tumor invasiveness and stemness were explored in vitro. Changes in expression levels of EMT and stemness factors were investigated by Western blot analysis and real-time polymerase chain reaction (PCR). Colony forming assay was performed in addition to invasion and migration assay. Selected EMT factor expression was examined in human glioma samples by immunohistochemistry and its effect on glioma patient survival rates was also analyzed.
Results: Established hypermotile glioma cell lines showed enhancement of invasion and migration capacity and also formed a larger number of neurospheres than original glioma cells. Of EMT markers, SLUG has been consistently increased by Western blot analysis and real-time PCR. Up-regulation of SLUG expression resulted in increased invasion capacity and knockdown of SLUG expression was associated with decreased invasion. While overall survival rates were not significantly affected by SLUG expression levels, the group with low SLUG expression had longer progression-free survivals than the group with high SLUG expression (P=0.042). In addition, infiltrating single glioma cells frequently exhibited strong SLUG expression in the invasion front of human glioblastoma samples.
Conclusions: Through establishment of hypermotile glioma cell lines using a repetitive scratch method, SLUG was named as a promising candidate that is expected to play a pivotal role in glioma progression in terms of invasive phenotype and stemness. More biological roles of SLUG in relation with chemoradiation need to be elucidated to set a potential therapeutic target. 1832
, secondary malignancy is a known complication. The genetic alterations underlying secondary gliomas arising after therapeutic radiation remain poorly characterized.
Design: Eleven gliomas arising after radiation treatment for childhood cancer were identified at our institution between 2008 and 2017, all of which were located within the radiation field. The cases were reviewed and studied by capture-based next-generation sequencing to assess approximately 500 cancer-associated genes for mutations, structural variants, and copy number alterations.
Results:
The most common primary malignancies were medulloblastoma (n=4), leukemia (n=2), and germinoma (n=2).
The average interval to glioma diagnosis was 15 years (range 4-40 years), including glioblastoma (n=5), anaplastic astrocytoma (n=4), pleomorphic xanthoastrocytoma (n=1), and low-grade glioneuronal neoplasm (n=1). All nine high-grade astrocytomas demonstrated markedly aneuploid genomes with several chromosomes per tumor demonstrating numerous segmental gains and losses consistent with "chromothripsis". Additional changes in these nine tumors included TP53 mutation (n=6), PDGFRA amplification and/or mutation (n=6), CDKN2A/B homozygous deletion (n=4), and CDK4 amplification (n=3). Three tumors harbored BRAF gene fusions or rearrangements, including the pleomorphic xanthoastrocytoma. The low-grade glioneuronal neoplasm demonstrated homozygous SMARCB1 deletion only. None of the 11 tumors had IDH1, IDH2, H3F3A, HIST1H3B, or TERT promoter mutations.
Conclusions:
The majority of gliomas arising after therapeutic radiation treatment are pathologically consistent with anaplastic astrocytoma or glioblastoma, which genetically differ, in part, from their spontaneous counterparts. They are characterized by marked aneuploidy, likely arising from the chromosomal breaks induced by gamma-irradiation. Furthermore, TP53, PDGFRA, CDKN2A, CDK4, and BRAF alterations are common. These findings identify a genetic signature of radiation-associated gliomas that is distinct from their spontaneous counterparts and suggest that different therapeutic strategies may be required for these secondary malignancies. are soft tissue sarcomas that can arise either sporadically or in patients with Neurofibromatosis type 1 (NF1). Recently, ATRX mutations had been identified in a subset of MPNSTs. We further explored its role in a relatively large cohort of sporadic and NF1-associated MPNSTs, as well as plexiform neurofibromas.
Design: Immunohistochemistry for ATRX was performed on a retrospective cohort of MPNSTs and plexiform neurofibromas diagnosed at two institutions.
Results: MPNSTs were more likely to display aberrant ATRX expression pattern (mosaic or loss) compared to plexiform neurofibromas (53% vs. 6%, p<0.01). Furthermore, aberrant ATRX protein expression was associated with a significantly decreased overall survival in NF1-associated MPNSTs [median survival 14.5 months (aberrant ATRX expression) vs. >120 months (retained ATRX expression), p=0.01], while there was no difference in overall survival based on ATRX protein expression pattern for sporadic MPNSTs [median survival 80.7 months (aberrant ATRX expression) vs. 94.4 months (retained ATRX expression), p=0.81].
Conclusions: In contrast to plexiform neurofibromas, aberrant ATRX protein expression is seen in a large subset of MPNSTs. Of note, this aberrant ATRX protein expression is associated with decreased overall survival in NF1-associated MPNSTs, but not sporadic MPNSTs. These observations hint towards a potentially distinct biology of the nerve sheath tumors in the two groups, and beg further investigation. 
Design: Sixteen cases of atypical pituitary adenomas (M:F = 12:4, age 15-74) and 20 randomly selected cases of non-atypical pituitary adenomas (M:F = 12:8, age 24-79) were collected from our institution. Demographic information, tumor size, functional status, hormonal positivity by immunohistochemical (IHC) staining, and mitotic rate were compared between the two groups.
Results:
The mean age at diagnosis of patients with atypical adenomas was 39.5 versus 49 for patients with non-atypical adenomas (Student's t-test, p value = 0.039). 50% of atypical adenoma patients were less than 40 years compared to 15% of non-atypical adenoma patients (chi-square test, p value = 0.023). 77% of atypical pituitary adenomas measured greater than 3 cm compared to 31% of nonatypical adenomas (chi-square test, p value = 0.036). Lastly, 56% of atypical adenomas were found to be IHC hormone positive compared to 20% of non-atypical adenomas (chi-square test, p value = 0.024). The differences in patients' gender, functional status of the tumors, and rare mitotic figures are not statistically significant. Background: Glioblastoma (GB) is one of the most vascularized human tumors. We have recently shown that GB is able to produce all vascular endothelial growth factor (VEGF) isoforms and that its sensitivity to anti-angiogenetic therapy may depend on the relative amount of the various isoforms. The diffusible VEGF-121 isoform could play a major role in the response of recurrent glioblastoma to treatment with bevacizumab. We hypothesized that circulating VEGF-121 may reduce the amount of bevacizumab available to target the heavier isoforms of VEGF, which are the most clinically and biologically relevant.
Design:
We assessed the plasma level of VEGF-121 in a brain xenograft model, in human healthy controls, and in patients suffering from recurrent GB before and after bevacizumab treatment. We also evaluated the relationship between the VEGF-121 plasma level and the tumor size in xenograft and contrast enhancing tumor (CE) area in patients. Data was matched with patients' clinical outcome.
Results: In athymic rats with U87MG brain xenografts, the level of plasma VEGF-121 relates with tumor volume and it significantly decreases after intravenous infusion of bevacizumab. Patients with recurrent GB show higher plasma VEGF-121 than healthy controls (p=0.0002) and treatment with bevacizumab remarkably reduced the expression of VEGF-121 in plasma of these patients (p=0.0002). Intesrestingly the VEGF-121 plasma level directly correlated with the VEGF-121 mRNA in the tumor and with CE area at the MRI. Higher plasma level of VEGF-121 and higher ΔVEGF-121 (VEGF-121 pre bevacizumab infusion -VEGF-121 after bevacizumab infusion) predict worse PFS and OS (p=0.0001 and p=0.0003, and p=0.0013 and p=0.0008, respectively).
Conclusions: VEGF-121 plasma level in the recurrent GB reflect the size and the angiogenetic process in the tumor. Quantitative analysis of VEGF-121 isoform plasma level is a biomarker for patients with recurrent GB tumors, predicting the response to anti-angiogenetic treatment. Background: MUC4 is a high molecular weight transmenbranous glycoprotein that plays a role in a cell growth signaling pathway and expressed in various epithelia to serve protective roles. The gene expression profiling assay and the immunohistochmeical analyses revealed that MUC4 is also constantly and specifically expressed in low grade fibromyxoid sarcomas and sclerosing epithelioid fibrosarcomas among the mesenchymal tumors and its immunohistochemical detection is extremely useful for their diagnoses. Incidentally, we noticed that meningiomas are often positive for MUC4 in our routine pathological practice and this finding still remains poorly investigated, despite the extensive scrutiny of its expression in soft tissue tumors.
MUC4 expression in meningiomas:
Design:
We immunohistochemically examined the expression of MUC4 in 43 meningiomas of variable histological subtypes, including 5 extracranial tumors (2 in spinal cord, 2 in middle ear, 1 in paranasal sinus). Ten intracranial schwannomas, 4 meningeal solitary fibrous tumors, 6 hemangioblastomas and 2 sinonasal glomangiopericytomas were also tested.
Results: In the 43 meningiomas, 40 (93%) expressed MUC4, at least focally (6/9 in fibrous, 8/8 in meningothelial, 4/4 in angiomatous, 1/1 in secretory, 7/7 in other grade 1 subtypes, 1/1 in clear cell, 8/8 in atypical, 5/6 in anaplastic). MUC4 expression was much more common in meningothelial or epithelioid cells than spindle or fibrous cells. The positive tumor cells were only scattered and limited in <5% of tumor cells in 5 tumors, but other tumors showed the diffuse or localized expression (median, 40% of tumor cells). Among the tumors with limited expression or negativity of MUC4, 6 were fibrous subtype, 1 each was psammomatous, atypical and anaplastic. All the schwannomas, solitary fibrous tumors, hemangioblastomas and sinonasal glomangiopericytomas examined were negative for MUC4. Background: Pediatric (PD) supra-tentorial diffuse gliomas are rare central nervous system tumors. PD patients are usually treated according to adult therapeutic regimens even though PD gliomas develop along distinct genetic pathways compared to their adult counterparts. The main objective of this work was to study PD supratentorial diffuse gliomas diagnosed at our institution, to identify distinct mutational and prognostic subgroups.
Conclusions:
Design: Thirty eight cases were studied by immunohistochemistry (antibodies against H3K27me3, IDH1-R132H, ATRX, p53, BRAF-V600E, MSH6, PMS2, MLH1, MSH2). Sanger sequencing of IDH1/2, HIST1H3B, H3F3A, BRAF and FGFR1 genes and pangenomic SNP arrays were performed. Clinical, radiological and survival data were obtained for each patient.
Results: Four mutational subgroups were identified, associated with significantly different overall survival, location (hemispheric vs midline) and age at diagnosis (p=0.007, 0.001, 0.002, respectively). The subgroup "H3K27M mutant gliomas" (31% cases), defined by a H3K27M mutation, was comprised of midline tumors (100%) in children (median age 11.3 years) with a poor outcome (median overall survival 8.6 months). The subgroup "H3G34R mutant gliomas" (8% cases), defined by a H3G34R mutation, was comprised of hemispheric tumors with ATRX mutation (100%) in teenagers (median age 15.2 years). Prognosis seemed better compared to that of H3K27M mutant gliomas. The subgroup "IDH mutant gliomas" (16% cases), defined by an IDH mutation, was comprised of hemispheric tumors arising in young adults (median age 23.5 years) with ATRX mutation and no 1p/19q codeletion (diffuse astrocytomas) and the longest survival. The last subgroup "wild-type (WT) gliomas", WT for IDH1/2, H3.3/H3.1, BRAF and FGFR1 genes, comprised 45% of the cases. These tumors, mostly hemispheric, affected younger children (median age 8.9 years) with a median survival time of 22.7 months. No constitutional mismatch repair deficiency syndrome was detected in the WT subgroup.
We have identified 4 mutational subgroups (H3K27M, H3G34, IDH and WT) significantly associated with distinct age, tumor location and prognosis. Driver genes are yet to identify in WT gliomas; such an identification will require high throughput sequencing techniques. Molecular classification of PD supra-tentorial diffuse gliomas is an essential step in the management of the patients and should allow personalized therapeutic approaches in the near future. Chohnam National University Hwasun Hospital, Hwasun-gun , Jeollanam-do Background: Although ZEB1, a key induce of epithelial mesenchymal transition (EMT), has been reported to promote tumor invasion and metastasis in various cancers, the role of ZEB1 in malignant gliomas has not been fully investigated. The aim of this study was to investigate the effect of ZEB1 on biological behaviors in human gliomas cell lines and on patient survival data.
Design: To evaluate the role of ZEB1 in glioma invasiveness, cell invasion and migration capabilities were investigated after ZEB1 knockdown using small-interfering RNA. ZEB1 expression was examined in 89 human glioma samples by immunohistochemistry.
Comparison of ZEB1 expression in each histological grade, and its effect on glioma patient survival rates were also analyzed.
Results: ZEB1 knockdown resulted in significantly reduced cell invasion and migration in U251 and T98G cell lines. ZEB1 downregulation also caused diminished expression of EMT related factors and genes by Western blotting and RT-PCR. ZEB1 expression, however, did not correlate with WHO tumor grades, overall survival rates, and progression free survival. Kaplan-Meier analysis did not reveal statistically significant difference of survival period between the high ZEB1 expression group and the low expression group in our patient cohort as well as in the large data set, Repository for Molecular Brain Neoplasia Data (REMBRANDT) by National Cancer Institute (NCI). IV) . Histologically-based diagnoses belie a molecular heterogeneity within this spectrum of tumors that can be revealed by molecular methods such as whole exome sequencing as well as more targeted cancer panels. Herein we summarize our findings in an adult IA cohort enrolled as part of a precision medicinebased clinical trial at a single institution.
Design: We interrogated 85 IA samples over 81 distinct adults (4 DA, 20 AA, and 61 GBM), including 12 IDH-mutated astrocytomas. Whole exome sequencing was performed on fresh frozen or FFPE tumor tissue and matched peripheral blood samples for germline analysis; RNA-seq was done in a subset of samples. We present a summary of our findings as well as a comparison to more targeted approaches, such as the FoundationOne® sequencing panel (FO) available in 68 (80%) of cases, in order to assess distinct approaches to the molecular characterization of IA.
Results:
The most frequently altered genes detected by both WES and FO include EGFR, CDKN2A/B, TP53, PTEN, NF1, IDH1, ATRX, and PIK3CA. Certain alterations such as TERT promoter mutations, which were present in the majority of IDH-wildtype IA's as detected by FO, were not assessed by WES. Several mutations in cancer related genes were revealed to be germline alterations in the WES pipeline alone, including in ARID1A, BRCA1, NF1, and WT1.
Conclusions:
The majority of the most common recurrent genetic alterations in the spectrum of IA are reliably detected by WES and at comparable rates to more targeted panels such as FO; however exome sequencing pipelines should be tailored to additionally cover highly recurrent somatic alterations occurring within introns and promoters, such as TERT, and would benefit by higher coverage of critical regions. Germline assessment is important both for the interpretation of alterations detected in tumor tissue as well as for the overall management of the patient who may be at risk for multiple neoplastic processes.
Does Post-Mortem Pituitary Histopathology
Correlate with the BMI? Cleveland, OH Background: The link between chronic systemic inflammation and obesity has been well established, and may operate via stimulation of the hypothalamic pituitary axis by pro-inflammatory cytokines. Elevated plasma ACTH levels have also been correlated with excessive body weight. Additionally, little is known about the incidence of hypophysitis in the general population or its prevalence in obesity. Similarly, the incidence of ACTH hyperplasia/adenoma in obesity has also never been systematically studied. We therefore investigated the prevalence of hypophysitis and adenohypophysial hyperplasia/ adenoma in our autopsy population in order to determine whether either of these histopathological abnormalities were overrepresented in patients with obesity.
Design: We retrospectively reviewed the histopathology of seventy two pituitaries removed from adult subjects at the time of autopsy between 2010 and 2017 at UHCMC. Cases with inflammatory CNS diseases were excluded (11 cases). The clinical history, body mass index (BMI) and cause of death were recorded. H&E, reticulin and IHC stains for ACTH, CD3 and CD20 were reviewed by two pathologists. Fisher and Chi square statistical tests were used.
Results: The patients were divided into 2 groups based on BMI: nonobese (BMI <30, N=29) and Obese (BMI ≥30, N=32), with mean ages of 59 and 57 years, respectively. The main cause of death was cardiac in both groups. Concomitant malignancies (predominantly pulmonary) were slightly more common in the non-obese group. Microscopic foci of inflammation were identified in 9 non-obese and 1 obese, (39.1% vs. 10.0%, respectively, P=0.12) consisting predominantly of T lymphocytes at the adeno-neurohypophysial junction. Pituitary hyperplasia/adenoma, non-corticotroph, was identified in 6 obese and 1 non-obese subject (18.7% vs 3.4%, respectively, P=0.1) . Variable amounts of adenohypophysial fibrosis was seen in 10 obese and 8 non-obese subjects.
Conclusions: Obese and non-obese patients demonstrated no significant differences in ACTH related pituitary pathology, possibly related to our limited sample size. However, non-corticotroph related pituitary hyperplasia/adenoma was identified more frequently in obese patients, whereas hypophysitis was more common in the nonobese group. Additional investigations are underway to correlate these findings with pre-mortem clinical differences in these patient populations. In addition, we are further characterizing the pituitary hyperplasias/adenomas within our autopsy population. Conclusions: NeuN was a good marker for normal ganglion cells and was differentially expressed across pediatric and adult central and peripheral nervous system tumors, hinting at ontologic differences. It was not a generic marker for neuroendocrine tumors. NeuN was rarely expressed in neuroblastoma and downregulated in more matured neoplastic neuronal cells in ganglioneuroma and ganglioneuroblastoma. The diagnosis of ganglioneuromas vs nerve sheath tumor entrapping ganglions is often a diagnostic challenge, and NeuN positivity may aid in differentiating neoplastic ganglion versus entrapped normal ganglion. Lastly the finding of retained NeuN expression in GI mucosal ganglioneuroma prompts one to question if the ganglion cells are truly neoplastic in these lesions. Background: An important subset of patients with Alzheimer's disease (AD) present with atypical non-amnestic syndromes not explained by current staging schemes. Astrocytic tau accumulation increases with age but has yet to be well-characterized in relation to AD pathology and clinical presentation. Prior reports have linked tau-positive astrocyte clusters in the white matter with a primary progressive aphasia phenotype in AD. We hypothesized that coexisting astrocytic tau inclusions may change vulnerability of cortical networks and explain clinical heterogeneity.
NeuN Expression in
Design: We systematically mapped astrocytic tau inclusions throughout selected cortical and subcortical sections in an AD cohort (N=76) enriched for atypical syndromes.
Results: Astrocytic tau accumulation was seen in 67% of cases overall and often clustered in distinct anatomical regions. Using principal component analysis, we identified co-existence in frontal (aCC, MFG, IFG) as well as limbic areas (ITG, insular, entorhinal cortices). Logistic regression revealed no relationship between presence of astrocytic pathology and atypical presentation. However, we observed an increase in astrocytic pathology with age. When examining morphological subtypes, thorn-shaped astrocytes (TSAs) in the white matter were associated with history of traumatic brain injury (TBI), and the aCC demonstrated a higher density of TSAs with prior TBI (p<0.05). In depth analysis of the frontal and insular cortices revealed no significant role for astrocytic tau in producing bvFTD versus other AD syndromes; additionally, no correlation of executive function with astrocytic pathology was identified.
Conclusions: This study, the largest undertaken to date, does not support an association between astrocytic tau and AD clinical heterogeneity.
Categorizing Peripheral Neuropathy Utilizing Deep Learning
Nkechi Okonkwo Background: Morphometry allows for basic descriptions in quantitative terms and reveals minimal morphological differences between functional states. Clinically, morphometry has been used for objective diagnoses of peripheral neuropathies. Nerve morphometry evaluates individual nerve fibers manually, semi-automatically, or fully automated. Evaluation commonly includes number of axons, myelin sheath thickness, and the ratio of large vs. small-diameter axons. Because of the routine features used to categorize neuropathies, fully automated image analysis systems could be programmed to analyze nerve fibers but has not been well described. The aim of this study is to train a convolutional neural network (CNN) to recognize several pathological patterns of neuropathy.
Design: Toluidin-blue stained semithin sections from 23 peripheral nerve biopsy specimens were collected, including unremarkable biopsies and diabetic and vasculitic neuropathies. The data set consisted of high resolution nerve photomicrographs in transverse section. Hundreds of unique input images were generated from each image and fed into the network. Data augmentation was employed to improve generalizability performance of the network. 6 patients were sorted into the testing set and the rest were part of the training set.
A 13-hidden layer neural network was designed for the study. Hidden layers consisted of 12 residual and/or inception style layers with one fully connected layer and a three class softmax output. AUC was utilized as the primary performance metric. Accuracy, sensitivity and specificity were also calculated as secondary performance metrics. The network was trained using stochastic gradient descent with momentum. Due to the small patient size, statistical accuracy was evaluated by correct classification of each individual image patch for the unique patients in the testing set.
Results: Recognition of normal vs. abnormal had an accuracy of 86.5%, sensitivity of 71.0% and specificity of 99.5%. Overall macro AUC was 0.82. Accuracy was 75.5%, sensitivity was 0.63 and specificity was 0.92.
Conclusions:
In this proof of concept study with 23 patients, we demonstrate that CNN's can be used to assist pathologists in diagnosing diabetic and vasculitic neuropathies, and possibly other types of neuropathies. This technique, can be used in peripheral nerves with the advantage of being a less expensive, more efficient method for diagnosing neuropathies. Further development with a larger data set can be employed to improve performance.
Mutational Landscape and Risk of Tumor
Recurrence in Meningioma 
Design: Tumor samples (n=139) were profiled using next-generation sequencing methodology using a custom capture probe library for 36 genes. Variants were classified against publically available databases and based on allelic frequencies. Results were correlated with available whole-genome methylation and copy number profiles.
Results:
The most common variants were in NF2 [(67/244, 27% in 67 patients (45%)] of which 32 (48%) were associated with chromosome 22 loss. The most common somatic variants involved TRAF7 (13/95, 14%), AKT1/KLF4/PIK3CA (5/95, 5%), SMO (4/95, 4%), TERT promoter/ SMARCB1 (3/95, 3%), RIMS2 (2/95, 2%), and PTEN/SUFU/CDKN2C/ RGPD3/CREBBP/EPB41L3 (1/95, 1%). In 12/13 (92%) TRAF7 associated AKT1/KLF4/PIK3CA mutations as previously described but also RGPD3 and RIMS2 mutations. NF2 mutations associated TERT promoter/ TRAF7/PTEN/SMARCB1/SUFU/CDKN2C/RIMS2/CREBBP/EPB4113 mutations but were mutually exclusive with PIK3CA/SMARC1/AKT1/ KLF4/SMO mutations. All PIK3CA/TERT promoter/KLF4/PTEN/SUFU and most NF2 (38/67, 57%), TRAF7 (9/13, 69%), SMO (3/4, 75%), EPB41L3 (6/7, 86%) mutations associated with a previously described prognostically unfavorable methylation subgroup associated with an increased risk for meningioma recurrence. On survival analyses the presence of TERT promoter and PTEN somatic mutations, NF2, CDKN2C, and EPB41L3 variants were predictive of decreased recurrence-free survival (RFS) (log-rank p<0.0001; p=0.0275; p=0.0386; p=0.0325; p=0.0349); however only the presence of NF2 mutations remained associated with decreased RFS after adjusting for methylation subgroups, mitotic index, WHO/Simpson grades, sex, and copy number profiles (p=0.003; Hazard ratio=3.06; 95%CI=1.16-11.59). All SMARCB1/RGPD3/CREBBP/RIMS2 mutations associated with a previously described prognostically favorable methylation subgroup associated with a decreased risk for meningioma recurrence.
Conclusions:
The presence of NF2 mutations in meningioma patients is strongly associated with decreased RFS. Along with the WHO grade, mitotic index, methylation and copy number profiles, the NF2 mutation status could be used to better stratify the risk for tumor recurrence and potentially guide patient management. Results: The NGS data allowed a reliable classification of the analyzed gliomas. The typical molecular profile of oligodendrogliomas (1p/19q co-deletion, IDH mutation, TERT promoter mutation) and K27M mutant midline gliomas were confirmed in all cases. Astrocytomas (grades II and III) and glioblastomas could be broken down into three categories based on their molecular profile: (1) IDH mutant cases, (2) IDH wild-type astrocytomas and glioblastomas with a molecular profile that included a TERT promoter mutation as well as at least one of the following: combined chr. 7 gain and chr. 10 loss, EGFR mutation/amplification, or CDKN2A loss. 77% of IDH wild-type tumors fell into this category. The astrocytomas in this group were confirmed to lack glioblastoma type imaging features at the time of surgery but exhibited aggressive growth akin to glioblastomas and may represent IDH wild-type glioblastomas diagnosed early. (3) The remaining IDH wild-type tumors, without the above molecular alterations, were a diverse group with heterogeneous biology. This group included tumors with unique molecular features, for example, a glioblastoma with DNMT3B mutation as well as an anaplastic astrocytoma with BRAF L485F mutation and CDKN2A loss. The clinical behavior of the tumors in this third group is arguably difficult to predict based on current data. Based upon initial histological diagnosis, the cohort included glioblastomas (40%), astrocytomas (16%) meningiomas (11%), and oligodendrogliomas (9%) as well as small numbers of ependymomas, pilocytic astrocytomas, and schwannomas. Nine percent of the specimens were initially assigned the non-specific diagnosis of glioma. NGS data were analyzed and variants were assigned to one of three significance categories: clinically significant, variant of uncertain significance, or not reportable. Microarray data was used to identify genomic structural changes, including segmental gains, losses, focal gene amplifications, and copy-neutral events such as loss of heterozygosity.
Results: One or more reportable genomic alterations were detected by NGS in 71% of cases. The most commonly mutated genes were TP53 (39.4 % of cases), IDH1 (31.3%), PTEN (14.6%), PIK3CA (9.1%), EGFR (8.6%) and ATRX (8.1%). Reportable cytogenetic abnormalities were detected in 95% of cases, including chromosome 7 gains, chromosome 9, 10, or 22 loss, and co-deletion of chromosomes 1p/19q. Clinically significant variants (those of diagnostic value or targetable with therapeutics) were identified in 75% of cases overall. For the majority of cases, molecular categorization was consistent with the initial histologic diagnosis. In addition, for a subgroup of cases which were histologically ambiguous or especially challenging, the genomic profiling information allowed provision of a clear or refined diagnosis.
Conclusions: This study demonstrates the value of genomic profiling in the evaluation and ultimate classification of brain tumors and that targetable genetic alterations are frequently detected in these tumors. The histopathologic effects of MPTCP have not been described. The purpose of this study is to report the histologic changes of TCP and MPTCP treatment in cadaver eyes.
Design: Three pairs of adult eyes were obtained from eyebank, and superior and inferior halves were randomly assigned to TCP, single MPTCP, double MPTCP or control. Upon fixation, globes were examined under dissecting scope. Anterior halves of the globes were serially sectioned in the vertical axis into 3-5 slices. 12-15 step sections were examined for all tissue slices. Histologic features, scored as present or absent in each step section includes: 1-Split (between pigmented and nonpigmented epithelium), 2-Separation (of pigmented epithelium from stroma), 3-Coagulation (of collagen and destruction ciliary body stroma), 4-Destruction (of ciliary body epithelium). Discrete variables were compared using 4x2 Fisher's Exact test and logistic regression.
Results: 498 step sections of 46 tissue slices were examined. Changes were present only in some of the step sections of each tissue slice, and were limited to the pars plana. Table1 summarizes the distribution of findings. Separation and destruction of the epithelium were seen in TCP treated regions (p<0.001) while split was seen in all regions including the control. Stromal coagulation was more common in TCP-, but was also seen in single and double MPTCP-treated regions.
In a model adjusted for clustering of findings in step sections of the single tissue slice, TCP was more likely to show stromal coagulation than control (p=0.002); however, single or double MPTCP was not significantly different than control (p=0.35 and p=0.50). Design: To address these issues we performed a meta analysis from a total of 2,096 cases (H3K27M, n=1,036; WT, n=1,060) assembled from 74 studies (n=1,549), the cancer genome atlas (TCGA; n=260), and collaborative efforts (n=323).
Results: Across all tumor types and locations, overall survival (OS) was significantly shorter in H3K27M-mutated (n=500, median OS: 12.5) compared to H3WT tumors (n=595, median OS: 22) (Χ 2 =112.688, log-rank, p<0.001). Adjusting for grade, H3K27M vs H3WT showed significantly shorter OS in H3K27M brainstem (K27M, n=123; WT, n=32; Χ 2 =4.810, log-rank, p=0.028) and non-midline location tumors (K27M, n=15; WT, n=183; Χ 2 =4.505, log-rank, p=0.034). H3K27M vs H3WT OS comparisons within thalamic (K27M, n=78; WT, n=58) and cerebellar tumors (K27M, n=11; WT, n=39) were not significantly different. Circumscribed (localized) H3K27M gliomas (n=23) had significantly shorter OS than WT (n=68) (Χ 2 =6.722, log-rank, p=0.010). In subgroup analysis of location, OS was significantly different in H3K27M tumors: brainstem (median OS: 11.8) vs. thalamus (median OS: 13.5) (Χ 2 =7.708, log-rank, p=0.005) and brainstem vs. non-midline (cerebral hemispheres) (median OS: 15) (Χ 2 =5.008, log-rank, p=0.025). All other comparisons of OS by location were not significantly different. Infratentorial H3K27M tumors had significantly worse OS (median OS: 11.8) than supratentorial tumors as a whole (median OS: 14) (Χ 2 =8.437, log-rank, p=0.004).
Conclusions: In summary, H3K27M mutations were associated with a significantly worse prognosis compared to H3WT in brainstem, nonmidline and non-infiltrating gliomas. Johns Hopkins University School of Medicine, Baltimore, MD Background: Pilocytic astrocytomas (PA) are WHO grade I tumors typically occurring in children and young adults with excellent outcomes after surgical resection. Anaplastic changes in the form of brisk mitotic activity (with or without necrosis) may develop in a small subset and be associated with an aggressive behavior. The biologic features associated with this phenomenon are still unclear Design: A total of 34 patients (23 M, 11 F) with a mean age of diagnosis of anaplasia of 33 years (range 3-75) were included in the study. Cerebellum/posterior fossa location was most common (n=21), followed by supratentorial hemispheric (n=5), supratentorial intraventricular (n=3), tectum/pineal (n=2), spinal cord (n=2) and brain NOS (n=1). Clinical and demographic characteristics including NF1 status were abstracted from retrospective chart review. A clinical diagnosis of NF1 (or NF1 gene mutation) was present in 8 (24%). Alternative lengthening of telomeres (ALT)was tested using telomere specific FISH. A combination of immunohistochemistry, DNA sequencing and FISH were used to study BRAF, ATRX, p16, mutant IDH1 p.R132H and H3 p.K27M proteins.
Results: ALT was present in 20 (70%) cases and ATRX loss in 19 (61%), mostly in association (24 of 27, 89%). Discrepant results included ALT+/ATRX+ in 2 cases and ALT-/ATRX-in a single case with ATRX loss that was considered partial (i.e. present only in a subset of neoplastic cells). H3 p.K27M was present in 5 of 30 (17%) cases tested, 4 with concurrent ATRX loss and ALT. In 8 cases, ALT and/or ATRX was tested in the low grade PA component/precursor as well as the anaplastic PA. ALT/ATRX loss was present in both low grade and anaplastic components in 4 (of 5) cases, and was limited to the malignant component in a single case.
Conclusions: ALT and ATRX loss are frequent in anaplastic PA at the time of development of anaplasia or their precursors. Additionally, a small subset of anaplastic PA have H3 p.K27M mutations. These findings further support the concept that anaplastic PA is a distinct neoplasm with combined alterations typical of PA and diffuse gliomas. Design: The neuropathology and neurosurgery databases at our institution were searched for all cases of pineal region lesions resected between 1981 and 2017.
Results: A total of 360 lesions were identified in this predominantly adult cohort of patients. These included 91 pineal parenchymal tumors (25.2%), 90 glial tumors (25.0%), 83 germ cell tumors (23.1%), 27 pineal cysts (7.5%), 22 meningiomas (6.1%), 17 miscellaneous benign specimens (4.7%), 12 mesenchymal neoplasms (3.3%), 7 miscellaneous malignant lesions (1.9%), 6 glioneuronal tumors (1.7%), and 5 metastases (1.4%). The mesenchymal neoplasms included five solitary fibrous tumors (SFT)/hemangiopericytomas, two epithelioid hemangioendotheliomas, two lipomas, one hemangioblastoma, one malignant spindle cell neoplasm, and one sarcoma. Recurrence occurred in two patients with SFT/hemangiopericytoma and in the patient with an epithelioid hemangioendothelioma. A review of the literature expands the spectrum of mesenchymal neoplasms of the pineal region to include rhabdomyosarcoma, myxoid chondrosarcoma, osteosarcoma, angiosarcoma, and fibrosarcoma.
Conclusions: Although mesenchymal neoplasia within the pineal region is very rare, it is an important neoplastic subgroup that warrants consideration in the differential diagnosis of pineal region masses. 
Angers University Hospital
Background: Glioblastoma (GBM) is the most frequent and lethal form of diffuse glioma. GBM displays chromosome (chr) instability (CIN) and recurrent somatic copy number alterations (SCNA). Recently, two distinct genetic events have been identified in cancer patients: whole genome duplication (WGD) and chromothripsis (CT). Such events have not been well described in large GBM cohorts. These events may contribute to tumor genesis/progression and gene rearrangements.
Design: We used pan-genomic single nucleotide polymorphism (SNP) arrays to identify and characterize CT and WGD in 123 primary GBM. GAP (R package) was used to call somatic regions of copy number changes (CN) and determine the ploidy pattern for each tumor. The calling of CN changes was based on the analysis of logR and allelic ratios. WGD and CT were validated using, respectively, FISH technique and CTLPScanner, a web interface.
Results: CT occurred in 29.3 % of GBM (36/123) and mostly affected chrs 7, 9 and 12 (41.6%, 38.9%, and 4% of CT cases, respectively), with amplification of oncogenes (e.g., EGFR (chr 7), MDM2/CDK4 (chr 12)), and homozygous deletion of tumor suppressor genes (e.g., CDKN2A (chr 9)). WGD was detected in 11.4% of GBM (14/123). Losses were seldom associated with LOH in WGD GBM suggesting genome doubling is an early genetic event. However, it occurred after the recurrent SCNA (e.g., chr 10 and 9p losses) observed in diffuse highgrade gliomas. WGD was observed in both initial and corresponding recurrent tumors. GBM with WGD were more aneuploid compared to GBM without WGD (p< 0.0001) suggesting genome doubling facilitates CIN. WGD GBM tended to occur at a younger age compared to neardiploid GBM (55 years vs. 63 years, respectively; not statistically significant). There was no significant association between CT or WGD occurrence and overall survival.
Conclusions:
We identified CT and WGD in 29.3% and 11.4% of primary GBM, respectively. CT recurrently targets oncogenes and tumor suppressor genes known to be key players in gliomagenesis and tumor progression. The occurrence of CT points to underlying gene rearrangements (e.g., gene fusions), potential therapeutic targets in GBM. WGD is an early genetic event; it leads to CIN and aneuploidy. Such aneuploidy increases genetic variation and adaptive potential to a new or changing environment. Tumor cells with WGD may become resistant to radiation therapy and chemotherapy; hence give rise to tumor recurrence. Design: We performed a retrospective search of our pathology archives from 1995-2017 to identify lymphomas and reactive lymphoid infiltrates involving the conjunctiva. We evaluated the frequency and subtypes of different lymphomas, and studied the morphologic, immunophenotypic, molecular and cytogenetic features of lymphomas and reactive infiltrates involving the conjunctiva. We additionally studied associated clinical features.
Results: 183 biopsies with lymphoid infiltrates were identified. 98 were lymphomas and 85 were reactive infiltrates. The majority of lymphomas involving the conjunctiva were marginal zone lymphomas (MZL; 73/98) and follicular lymphoma (FL; 12/98) and to a lesser degree mantle cell lymphoma (MCL; 8/98). Interestingly, clinically localized FL of the conjunctiva is always low grade (10/10), and typically positive for BCL2 protein expression (8/10) though when evaluated, cases were negative by FISH for the BCL2 translocation (0/4). One systemic follicular lymphoma involving the conjunctiva was seen and showed grade 3A morphology. Mantle cell lymphomas involving the conjunctiva were systemic and never localized cases. Finally, our review of reactive infiltrates involving the conjunctiva suggests that reactive intraepithelial B-cell infiltrates are not uncommon. The influence of gender on the prognosis of uveal melanoma has historically been considered insignificant; but in recent years, data has emerged suggesting that there are differences between men and women. The purpose of this study is to confirm that estrogen receptors (ER) are present in a subset of uveal melanomas and to determine whether ER expression impacts patient outcome (metastasis or death) or relates to known genetic high risk features.
Design: Incidence and outcome data of 50 cases (47 patients) of UVM from 2010-17 were analyzed. The study was approved by the Ohio State University Wexner Medical Center IRB. Of the 50 cases, there were 41 enucleations, 3 iris excisions, 1 iridociliary excision, 1 choroid biopsy in a case of known liver metastasis, and 2 liver metastases. They were stained for ER by IHC using a brown chromogen. Cases were considered positive if at least 1% of the tumor nuclei stained and were scored by one ocular surgical pathologist who also has had extensive experience in breast pathology. Chromosome 3 and 8q status was determined by cytogenetics and/or FISH; in some cases, gene expression profiling (GEP) was also available. Patient outcome was obtained from the electronic medical record.
Background: Gliosarcoma (GS) is a rare subtype of glioblastoma (GBM) that features mesenchymal differentiation. Previous studies have found that GS shares many of the same molecular characteristics as GBM, and a subset of gliosarcomas possess abnormalities in the Wnt signaling pathway.
Design:
We recently came across five gliosarcoma cases at our institute that underwent next generation sequencing. We further assessed copy number changes, chromosomal imbalances, and single nucleotide variations in these tumors.
Results: There were 3 male and 2 female patients (age 15-74, median 59 years). In three of the cases, the tumor was located in the temporal lobe at initial presentation. One case involved the frontal lobe, and another case localized to the thalamus and brainstem. Notable chromosomal alterations included losses on chromosomes 10 (5/5, 100%) and 9p (3/5, 60%), and gains on chromosome 7 (4/5, 80%). Two single nucleotide variations were noted in Wnt signaling pathway genes, CSNK1A1 -chr5:149499672T>C and CTNNB1 -chr3:g.41267276A>G, in 4/5 and 1/5 cases, respectively. The former variation involves the 3' untranslated region of the gene's transcript, while the latter variation causes a missense mutation in exon 7 of the beta-catenin gene. To our knowledge, the effects of these specific variants on transcript processing and protein functioning have not yet been elucidated.
Conclusions:
Our results reinforce the notion that gliosarcoma and glioblastoma share many of the same molecular and cytogenetic features. Further investigation into the significance of Wnt signaling pathway alterations in the pathogenesis of gliosarcoma is of interest for its potential therapeutic implications. Washington University in St. Louis, Saint Louis, MO Background: Pilocytic astrocytoma (PA) is the most common benign brain tumor of childhood. Although most patients exhibit a benign course, a small subset of tumors recurs and demonstrate cerebrospinal fluid (CSF) dissemination. While BRAF alterations might act as therapeutic targets in such scenarios, there still remains a small subset of tumors that lack these alterations. Recently, the binding of PD-L1 to its receptor PD-1 has been shown to induce an immune escape mechanism and to play a critical role in tumor initiation and progression. Further, there is also an emerging role of immune cells (including microglia) in gliomagenesis. We investigated the role of common immune markers, PD-1, and PD-L1 in pilocytic astrocytomas.
Design: A tissue microarray containing 38 PA cases was prepared, and immunohistochemical analysis for CD3, CD20, CD21, CD68, CD163, Ki-67, PD-1, and PD-L1 was performed. The relationship between density of immune cells and Ki-67 proliferation index of the tumor was examined.
Results: Sparse-to-moderate density of tumor infiltrating lymphocytes was found in all PAs (CD3+ T cells varied from 0.4 to 17.6%, CD20+ B cells varied from 0.01 to 1.1%, and CD21+ dendritic cells comprised < 0.01% of tumor Background: Malignant glioma (MG) is one of the most aggressive neoplasm in human cancers. We have previously reported glialmesenchymal transition (GMT) by increasing in snail expression after irradiation was related to radio-resistance in MG (Neuro-Oncol. 2014). Although MG with IDH1 mutation has been reported to show better prognosis compared to MG with IDH1 wild type, it has not been clarified how the IDH1 mutation affects radio-sensitivity in MG.
Design: To investigate the role of IDH1 mutation on radiosensitivity, we first established IDH1 WT and IDH1 R132H overexpressing KMG4 and U87 MG cell lines using pCX4-puromycin-IDH WT and pCX4-puromycin-IDH R132H vectors and performed metabolome analysis by capillary electrophoresis-mass spectrometry. Second, to mimic irradiation therapy, we irradiated multi-fractionated 20 Gy to IDH1 R132H overexpressing MG cells (IDH R132H MGs) and IDH1
WT overexpressing MG cells (IDH WT MGs) and analyzed the apoptosis and EMT related molecules by immunoblotting and qRT-PCR. Lastly, we performed migration and invasion assays to evaluate malignant potentials.
Results: IDH R132H MGs showed lower levels of α-KG, NADPH, reduced GSH and ATP, while higher levels of 2-HG, oxidized GCH, ADP and AMP compared to IDH WT MGs. IDH1 R132H MGs showed a decrease in the phosphorylation levels of AKT and Bcl2 expression compared to IDH1
WT cells. In addition, IDH1 R132H MGs showed an increase in phosphorylation levels of p53 and cleaved PARP expression. Although snail mRNA was increased after irradiation compared to before in IDH1 WT MGs, it was not increased in IDH R132H MGs after irradiation. Furthermore, both motility and invasiveness were increased after irradiation in IDH1
WT MGs, however these phenomenon was not occurred in IDH R132H MGs.
Conclusions: IDH1 mutation induces changes in metabolic status and may lead to radio-sensitivity by regulating apoptosis and GMT leading to better prognosis in MGs. In this study, we examine the utility of using immunohistochemical stains for cyclin D1, L1CAM, and p65 --proteins involved in NF-kB signaling pathways --for detecting RELArearranged ependymomas.
Design: Immunohistochemistry for cyclin D1, L1CAM, and p65 was performed on sections of ependymomas from each anatomic location (supratentorial, n=17; posterior fossa, n=21; spinal cord, n=37), as well as several histologic mimics, including astroblastoma (n=2), gliomas with angiocentric architecture (n=6), and embryonal tumors (n=3). The staining profiles were correlated with array comparative genomics hybridization (aCGH) data, which were available for a subset of the cases.
Results: Evidence of C11orf95-RELA fusion was seen only in 4/5 supratentorial ependymomas for which microarray had been performed. Cyclin D1 was positive in 9/17 supratentorial ependymomas, including the 4 RELA-rearranged ependymomas, 1/21 posterior fossa ependymoma, and none of the spinal cord ependymomas, astroblastomas, gliomas with an angiocentric architecture, or embryonal tumors. L1CAM and p65 were positive in 8/17 supratentorial ependymomas, including all 4 RELA-rearranged ependymomas, and negative in all other tumors.
demonstrate a statistically significant difference in in AD severity as measured by Braak and Braak scoring (5.39 ± 0.87 vs. 5.38 ± 0.95) nor neurodegenerative HS pathology by TDP-43 staining. 
